Antiviral Investigation of Cassia alata L. bioactive compounds for SARS-CoV-2 Mpro: In Silico approach-Reference-Cited by-同舟云学术

Antiviral Investigation of Cassia alata L. bioactive compounds for SARS-CoV-2 Mpro: In Silico approach

Published:2023-12-29 Issue: Volume: Page:5610-5616
ISSN:0974-360X
Container-title:Research Journal of Pharmacy and Technology
language:en
Short-container-title:RJPT

Author:

Rahma Turista Dora Dayu¹,Dhea Kharisma Viol²,Muhammad Ansori Arif Nur³,Ahmedovna Kardanova Karina⁴,Ruslanovich Aslanov Islam⁴,Muhadinovich Dotkulov Ibragim⁴,Zamirovich Apshev Azret⁴,Albertovich Dokshukin Amir⁴,Rebezov Maksim⁵,Jakhmola Vikash⁶,Ullah Md. Emdad⁷,Zainul Rahadian⁸

Affiliation:

1. Department of Biology Education, Faculty of Teacher Training and Education, Mulawarman University, Samarinda, Indonesia.

2. Department of Biology, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia.

3. Postgraduate School, Universitas Airlangga, Surabaya, Indonesia.

4. Medical Faculty, Kabardino-Balkarian State University, Nalchik, Russian Federation.

5. Department of Scientific Research, V. M. Gorbatov Federal Research Center for Food Systems, Moscow, Russian Federation.

6. Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.

7. Department of Chemistry, Mississippi State University, Mississippi, United States.

8. Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, Padang, Indonesia.

Abstract

SARS-CoV-2 has caused a prolonged COVID-19 pandemic since the end of December 2019 and is still ongoing now. Bioactive compounds can be used as drugs to treat infectious diseases. This study aims to determine C. alata as a drug candidate for COVID-19 through its inhibitory activity to Mpro SARS-CoV-2 in silico. Cassia alata bioactive compounds have the potential to be used as a candidate for anti-SARS-CoV-2 supported by the result of drug-likeness, ADMET, pharmacokinetics, binding affinity, and antiviral activity prediction. Further research needs to be carried out to make C. alata a drug for COVID-19.

Publisher

A and V Publications

Reference46 articles.

1. Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264-266. doi:10.1016/j.ijid.2020.01.009

2. Turista DDR, Islamy A, Kharisma VD, Ansori ANM. Distribution of COVID-19 and phylogenetic tree construction of sars-CoV-2 in Indonesia. J Pure Appl Microbiol. 2020;14:1035-1042. doi:10.22207/JPAM.14.SPL1.42

3. WHO. Coronavirus disease (COVID-19). World Heamth Organization. Published 2022. Accessed November 30, 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019

4. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155-170. doi:10.1038/s41579-020-00468-6

5. Wina Nurtias LY, Rahma Turista DD, Puspitasari E. Human immune response to SARS-CoV-2 infection. J Teknol Lab. 2020;9(1):29-40. doi:10.29238/teknolabjournal.v9i1.223